definiens: means [ Ioddng of the database for anal,)'si.s of ' the, \oituciJ'.1, ' r ] shall be payable upon the [ complelion of a Phase III Clinical Trial for tbe negulalory Appro,,::.1 of the Product for the tre;ltment of Chcmothcrapy - ImJuc cd Anemia whose results, jf sut . 'ccssl'ul, would also support as ~I pivotal data for the : Regulatory Appro\'al of the Product for the treatment of Anemia uf ' CanCel ", ] I ' ) For clarity, the milestones for ( nAf ~ Ij\A suhmission 1'01 ' Ant'mia of Can('l ~rJ shall be payahle upon [ the ac(.'cptnncc of submission of an, ), Regulatory ~/latel'inls that . if appl"o\'cd, would result in the Rcgulatol'~ ' Approval of the Product for the trcfltm£'nt of Anemia of Cmu'cr ( inl'iuding, by WHy of exmnplc, ii ' such appro,'al is recei\rccl through n label c:\:pansion 01 " through incltlsion of Anemia of Cancel ' in an NDA / MAA for other inclicalions}.1 ( 51 For clarity, if fRcAulalor.y Appro\'al is rel'cived In a fOllnlry b. " trc.atin~ Anemia of Cancer and Cht'lllothcrapy - lndu{'cd Anernia as single indication, uoth approv.::!l ] milestones will be payable ! if such Rcgul.ator)1 Apprtwal would permit the : sale of the Product for lise in treclting both ~lIch indicntions . J $ [ 50.000.000 ] S[20.000.0 00 ] ~[.J5.000, 000 ] $ [ 15.oo0.000J S[IO, OOO.OOO [ $ [ IO.OOO.OOU ] $ 280,000,000 II ~ Ct : lnA I,~ tO~ t"IOl::NT I,\L I ..... FOR:\I,\T10,'I CONTA1NEb I~ TillS OOCU:\IENT,, \IARK!:O nY BRACKETS . IS FILED WITII TilE SECURITIES, \,'0'Cr . COIl I ~ IISSION PllRSU,\NTTO R(ll.£406 OF TilE SECURITIES ACT OF 19.1:\, AS " OED